OTTAWA, Feb. 23, 2012 /CNW/ - Rx&D President Russell Williams made the following statement today about
GlaxoSmithKline plc's new funding of $12 Million to support an
additional three-years of research to monitor seasonal influenza
vaccine effectiveness in the elderly.
"Today's announced investment by GlaxoSmithKline will help advance
research already undertaken by supporting the tracking of the incidence
and severity of diseases in elderly adults hospitalized with influenza
across Canada. This funding will ensure key infrastructure will
continue as surveillance research will be conducted in 40 hospitals
across Canada comprising approximately 17,000 adult acute care beds,
including sites in New Brunswick, Nova Scotia, Quebec, Ontario,
Manitoba and British Columbia."
"This announcement reflects the shared commitment by Canada's
research-based pharmaceutical industry to work with partners to invest
in the health and prosperity of Canadians."
"It is by working together that we can secure Canada's position as a
world leader in developing and delivering new health care solutions to
people across Canada and throughout the world. Creating a more
favourable environment for investment, by improving Canada's
intellectual property and access regimes, would help secure additional
life sciences investments in Canada by the innovative pharmaceutical
sector. These investments are good for Canada and good for Canadians."
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: